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Abstract  
 Context. Integrated interventions with combined elements of body movement and 
psychotherapy on treatment-related symptoms in cancer patients are relatively scarce.  
 Objectives. The present study aimed to study the effectiveness of dance movement 
therapy (DMT) on improving treatment-related symptoms in a randomized controlled trial. 
 Methods. A total of 139 Chinese patients with breast cancer awaiting adjuvant 
radiotherapy (RT) were randomized to DMT or control group. The intervention included six 
1.5-hour DMT sessions provided twice a week over the course of RT. Self-report measures on 
perceived stress, anxiety, depression, fatigue, pain, sleep disturbance, and quality of life were 
completed before and after the three-week program. 
 Results. DMT showed significant effects on buffering the deterioration in perceived 
stress, pain severity, and pain interference (Cohen d = 0.34 to 0.36, P < 0.05). No significant 
intervention effects were found on anxiety, depression, fatigue, sleep disturbance, and quality of 
life (Cohen d = 0.01 to 0.20, P > 0.05).  
 Conclusion. The short-term DMT program can counter the anticipated worsening of 
stress and pain in women with breast cancer during radiotherapy. 
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Introduction 
Adjuvant radiotherapy (RT) is used to reduce the risk of loco-regional recurrence in women 
with breast cancer (1, 2). Patients undergoing RT often experience multiple distressing symptoms 
including pain, fatigue, heightened stress, and sleep disturbance, with reported occurrence rates 
of over 60% near the end of RT (3-5). Although these symptoms may appear as inevitable, 
short-term side effects of RT, a significant proportion of patients with breast cancer continue to 
experience them long after treatment completion (6-8). These symptoms have been associated 
with poorer quality of life (9). Their high prevalence and tendency to co-occur warrant 
intervention (10). Because of their multiple causes and concerns over interactions with 
concurrent RT, symptom treatment during active RT is a challenging task. 
A large volume of research has investigated the use of non-pharmacological interventions to 
alleviate treatment-related symptoms in cancer patients. Research evidence supports the use of 
physical movement to relieve fatigue (11) and psychotherapy for pain control (12), with the latter 
encompassing a wide range of therapies including cognitive therapy, behavioral therapy, and 
hypnosis. However, multiple remedies for various symptoms may necessitate frequent travel 
entailed by daily RT treatment and add to the patients’ burden. An integrated intervention with 
combined elements of movement and psychotherapy could be more effective. Yet, research in 
this area is relatively scarce. 
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Dance movement therapy (DMT) is a movement-based psychosocial intervention that 
incorporates the therapeutic components of dance movement and group psychotherapy (13). As 
defined by the American Dance Therapy Association, DMT uses guided and self-initiated 
movements to further the emotional, cognitive, physical and social integration of the individual 
(14). DMT emphasizes the interconnection between the body and mind such that one can express 
his mind through body movements (15). It enables the patients to enhance self-expression, accept 
and reconnect with their bodies, cope with feelings of depression and fear, rebuild 
self-confidence, and to strengthen personal resources (16). The group approach allows them to 
share their emotions, concerns, and coping strategies with others who are undergoing similar 
experiences and establish mutual social support (17).  
Previous research studies have reported positive results on the use of DMT on cancer 
patients (17-21). The majority of these studies are, however, not randomized controlled trials 
(RCT) and only have small sample size with relatively low statistical power. Bradt and 
colleagues (16) recently reviewed two RCT studies on the therapeutic effects of DMT on cancer 
patients. Their Cochrane review suggests DMT to have a beneficial effect on quality of life, 
somatization, and vigor but not on anxiety, depression, fatigue, stress, and body image. It 
remains unclear whether these findings are due to ineffectiveness of the treatment, unsuitable 
outcome measures, or limited number of RCT studies. To our knowledge, the effects of DMT on 
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patients receiving active cancer treatment have yet to be studied. More RCT studies are needed 
to elucidate the effects of DMT on physical and psychological outcomes in cancer patients.  
The current study aims to explore the changes in treatment-related symptoms (fatigue, 
anxiety, depression, pain, perceived stress, and sleep disturbance) and quality of life in a sample 
of Chinese patients with breast cancer during the course of RT. We have reported the qualitative 
outcomes of the study elsewhere (22), where DMT was found to provide benefits in terms of 
coping with cancer, treatment, and physical symptoms and improving mental well-being, 
attention, and appreciation for the self and body. In this quantitative analysis, we investigate the 
effectiveness of DMT in symptoms relief in patients with breast cancer . Previous research 
showed that fatigue or pain levels typically increase during RT, but their patterns over treatment 
vary by studies (23). It was hypothesized that a brief DMT intervention over the course of RT 
would benefit the patients by buffering their treatment-related symptoms while the symptoms 
would worsen in women who did not receive DMT.  
Methods 
Study Design 
This was a randomized controlled single-blind trial. Simple randomization was carried out 
with computer generated random numbers to randomize participants into either intervention 
(DMT) group or waitlist control group. Allocation concealment was carried out by research 
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assistants using sequentially numbered, opaque, sealed envelopes. Only the participants were 
blinded to the group allocation. The treatment group received DMT program during the first 
week of RT and the DMT program continued for three weeks. The waitlist control group 
received standard care during the course of RT and the same DMT program after collection of 
follow-up data three weeks later. 
The procedures of this study were in accordance with the ethical standards of the 
Institutional Review Board of the University of Hong Kong and Hong Kong Hospital Authority 
(Reference number: UW 10-118). Ethical approval was obtained from the institutional review 
board of the University of Hong Kong prior to start of the study. The trial was registered with the 
Clinical Trials Centre of the University of Hong Kong (HKCTR-1077). Written informed 
consent was obtained from all participants in the study. 
Participants 
 Patients with breast cancer awaiting the initiation of RT or during the first week of 
adjuvant RT were recruited from two public hospitals and three community cancer support 
centers in Hong Kong between December 2011 and February 2013. RT for breast cancer patients 
in Hong Kong was carried out over an average span of 25 - 30 days that lasted around 5 – 6 
weeks, depending on the type of surgery. Women who were ethnic Chinese aged 18 years or 
above with stage 0 to III primary breast cancer were eligible if they did not have any of the 
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following conditions: recurrent breast cancer, history of other cancers, history of psychiatric 
illness or physical disabilities that rendered them incapable of joining the DMT program. 
Calculation for sample size and power was performed for the regression of change in outcome 
variables on the treatment condition using Monte Carlo simulations (24). According to prior pilot 
studies (17, 21), we anticipated a medium effect size (Coden d = 0.63). Under the 0.05 
significance level and an assumed attrition rate of 7.1%, a sample size of n = 140 was found to 
provide a statistical power of 80.0% for the medium effect size.  
The flow of the study is presented in Fig. 1. A total of 317 eligible women were referred by 
the oncologists or medical social workers at the recruitment sites and subsequently contacted by 
a research assistant. Each potential participant received an invitation letter with details of the 
study. A hundred and seventy women declined to participate, mostly due to a lack of time or 
other personal reasons (response rate of 46%). Eight women withdrew after randomization (5% 
drop-out) due to personal reasons such as tight schedule, having previous engagement, not being 
able to commit to data collection etc., leaving 69 participants in the DMT group and 70 in the 
waitlist control group (total n = 139) for the analysis.  
Intervention 
The DMT program used for this study originated from the West and was modified by the 
first author to suit the Chinese culture, which values modesty, emotional control, and respect for 
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authority. It has been used in local populations with good outcomes and acceptance (17, 25). The 
program consisted of six 1.5-hour DMT sessions held twice a week for three consecutive weeks 
over the course of RT. The program was specially tailored to meet the needs of patients with 
breast cancer, including stretching, relaxation exercises, movement games and rhythmic body 
movement to exercise the upper extremities, improvisational dance and movement to explore 
positive emotions. Interactions, emotional expressions and communications were encouraged 
among the group members in the sessions. Simple group dances and group sharing were carried 
out to relate the movement process to participants’ personal experiences of breast cancer and 
cancer treatment. The sessions took place in the hospital, the community cancer support center, 
and the University of Hong Kong. Each group comprised 6-10 women, and women in the same 
groups went through the six sessions together. All sessions were led by a qualified dance 
movement therapist. The waitlist control group did not participate in the intervention program 
but received radiotherapy and standard nursing care in the hospitals.  
Data Collection 
Outcome data were collected via self-administered questionnaires before the start of the 
DMT program (pre-RT) and at 3-week follow up upon the completion of the program (end-RT). 
The self-report questionnaires were completed at home and returned to the research team by post. 
The self-report questionnaire included validated measurement scales on the following outcomes: 
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10 
perceived stress, anxiety, depression, fatigue, pain, sleep disturbance, and quality of life. Clinical 
and demographic data were also collected at pre-RT. In the DMT group, over 90% of the 
participants attended five or more sessions. In addition, in the last DMT session, qualitative 
feedback was sought from the participants on whether and how the program helped them during 
the RT. Over 93% of the participants provided data at end-RT, with attrition rates of 4.3% and 
8.6% for the treatment and control groups, respectively.  
Outcome Measures 
The Perceived Stress Scale is a 10-item, 5-point measurement scale that measures 
respondents’ subjective global experience of stress (26). The total score ranges from 0 to 40 and 
higher scores indicate higher levels of perceived stress. The Hospital Anxiety and Depression 
Scale is a 14-item, 4-point scale used to measure depression and anxiety symptoms (27). The 
total scores for anxiety (7 items) and depression (7 items) range from 0 to 21, with higher scores 
indicating worse mental health status. The Brief Fatigue Inventory is a 9-item, 11-point 
assessment scale of fatigue severity and its interference with daily functioning (10). The total 
scores for fatigue severity (3 items) and fatigue interference (6 items) range from 0 to 10, with 
higher scores indicating more severe fatigue.  
The Brief Pain Inventory is a 11-item, 11-point measurement scale of pain severity and its 
interference with daily functioning (28). The total scores for pain severity (4 items) and 
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interference (7 items) range from 0 to 10, with higher scores indicating more severe pain. The 
Pittsburgh Sleep Quality Index is a 7-component, 4-point measurement scale of sleep disturbance 
(29). The seven component scores are summed to produce a global measure of sleep disturbance, 
with higher scores denoting poorer sleep quality (range = 0 – 21). The Functional Assessment of 
Cancer Therapy – Breast scale is a 36-item, 5-point instrument that assesses quality of life of the 
patients in physical, social, emotional, functional, and breast cancer specific domains (30). The 
total score for quality of life ranges from 0 to 144, with higher scores denoting better quality of 
life. All of the Chinese version of the measurement scales showed good reliability (α > 0.75) in 
the current study. 
Statistical Analysis 
 Independent samples t-tests and Chi-square tests were conducted using SPSS 20 to 
compare the demographics and baseline characteristics of the two groups. Attrition analysis was 
performed to compare the profiles of the study dropouts (n = 9) and the completers (n = 130). 
Traditional analytic techniques such as analysis of variance (ANOVA) adopt listwise deletion or 
substitution methods (31) and may not yield precise estimates in the presence of missing data. In 
this randomized trial, latent growth modeling was used to evaluate the intervention effects via 
maximum likelihood estimation in Mplus 7 (32). This technique analyzes changes in outcome 
variables over time and achieves intent-to-treat analyses by including all available data in the 
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model via full information maximum likelihood (33). The change trajectories of the outcome 
variables were examined in the overall sample via unconditional growth modeling. All statistical 
tests were two-sided.  
A linear trend was fitted on each outcome variable and the growth models were identified 
by fixing the residual variances of the repeated measure at zero. For the analysis of DMT effect, 
we regressed the changes in outcome variables on the treatment condition via conditional growth 
modeling. In the conditional model, age was included as a control variable to increase the 
statistical power of detecting treatment effects. Model fit was evaluated using the following 
criteria for the fit indices: insignificant chi-square (χ2), comparative fit index (CFI) ≥ 0.95, 
Tucker-Lewis index (TLI) ≥ 0.95, root mean square error of approximation (RMSEA) ≤ 0.06, 
and standardized root mean square residual (SRMR) ≤ 0.08 (34). Cohen’s d reflects the 
standardized between-group slope difference, with values of 0.2, 0.5 and 0.8 denoting small, 
medium and large effect sizes, respectively (35).  
Results 
Demographic and Clinical Characteristics 
 Table 1 presents the demographic and clinical characteristics of the participants by 
treatment group. The mean age of the participants was 48.9 years (SD = 8.2) and they on average 
received 9.5 (SD = 8.2) days of radiotherapy sessions at the start of the study. The majority of the 
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participants attained secondary educational level (65%), were married (63%), and had undergone 
breast conserving surgery (59%) and chemotherapy (80%). The two groups did not differ 
significantly in the demographic and clinical characteristics.  
The descriptive statistics of outcome variables by treatment group are shown in Table 2. 
No significant difference (P > 0.05) was found in the outcome variables at pre-RT across the two 
groups. Comparisons on the profiles of the study dropouts (n = 9) and the completers (n = 130) 
showed that at pre-RT the dropouts were significantly younger (M = 42.1 vs. 49.3, P < 0.05) and 
had significantly lower sleep disturbance (M = 5.2 vs. 7.5, P < 0.05) and better quality of life (M 
= 114.0 vs. 96.3, P < 0.01). In a descriptive sense, participants in the DMT group had slight 
improvement in all measures except anxiety and depression. For the control group, participants 
showed slight decreases in depression, fatigue severity, fatigue interference and quality of life 
but increases in perceived stress, pain severity, pain interference, and sleep disturbance.  
Analysis of Treatment Effects 
 The unconditional growth models fitted the data well with insignificant χ2, CFI and TLI > 
0.97, RMSEA < 0.06, and SRMR < 0.08. The overall sample reported significant decreases in 
fatigue severity (△ = -0.39, SE = 0.20, P < 0.05) and fatigue interference (△ = -0.52, SE = 0.17, 
P < 0.01). There were no significant changes in perceived stress (△ = -0.58, SE = 0.34, P = 
0.08), quality of life (△ = 1.93, SE = 1.03, P = 0.06), anxiety (△ = -0.07, SE = 0.20, P= 0.72), 
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depression (△ = -0.32, SE = 0.27, P= 0.22), pain severity (△ = 0.19, SE = 0.18, P= 0.30), pain 
interference (△ = 0.12, SE = 0.18, P = 0.53), and sleep disturbance (△ = -0.26, SE = 0.22, P= 
0.25).  
The conditional growth model provided an adequate fit to the data with insignificant χ2, 
CFI and TLI > 0.96, RMSEA and SRMR < 0.06. As shown in Table 3, there were significant 
DMT effects on perceived stress, pain severity, and pain interference but not on anxiety, 
depression, fatigue severity, fatigue interference, sleep disturbance, and quality of life. The 
model estimated trajectories for perceived stress, pain severity, and pain interference are shown 
in Fig. 2. There was a decrease in these outcome variables in the DMT group in contrast to an 
increase in the control group. The effect sizes of the DMT treatment were of small to medium 
magnitude (Cohen d = 0.33 - 0.36) on the outcome variables. 
Discussion 
In the present study, latent growth modeling analyses demonstrated significant effects of 
DMT on stress, pain severity and pain interference compared to control condition. Consistent 
with previous findings (3-5), the control group showed an increase in perceived stress, pain 
severity, and pain interference over the course of RT. In contrast to Dibbell-Hope’s study (18), 
the only other RCT study that examined the effects of DMT on our outcomes, our study showed 
small but significant improvements in perceived stress for DMT over RT. The use of spontaneous 
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movement and rhythmic action in DMT enables participants to relax and express their feelings 
nonverbally and freely (16), thereby allowing them to release their psychological tension. The 
group psychotherapy component of DMT likely provides social support to the participants and 
helps them overcome their isolation through rhythmic sharing. These could, in turn, contribute 
lower levels of perceived stress. 
 The DMT group reported significant improvements in pain severity and pain interference 
over RT, with proportional improvements in comparison to the control group exceeding 25%. 
These results resemble similar findings on the beneficial effects of body movement on pain 
among cancer patients receiving chemotherapy (36). The body-oriented approach of DMT could 
improve range of arm motion and shoulder function, release muscular tension (13, 37), and 
promote patients’ self-awareness of their own body. These might foster a greater internal focus of 
control and provide relief from the symptoms by shifting the focus away from the unpleasant and 
painful RT experiences (15). These elements could contribute to effective pain control. Given the 
potential clinical value of DMT in pain reduction, DMT could be incorporated as part of an 
integrative cancer care treatment for prophylactic pain control at the onset of RT to facilitate 
early intervention. 
Though Sandel and colleagues (19) reported a large treatment effect of DMT on quality of 
life, our DMT group showed no significant improvements on sleep disturbance and quality of 
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life. The lack of significant findings could be attributed to the short duration (3 weeks) between 
the pre and post assessments. Given the time constraint in relation to the radiotherapy treatment 
duration for the intervention, dramatic changes in quality of life were not expected. Consistent 
with Dibbell-Hope’s study (18), no significant effects were found for the DMT program in 
anxiety, depression, and fatigue in the present study. Interestingly, fatigue severity and 
interference decreased for both DMT and waitlist control groups over RT. Though such declines 
in fatigue stood in contrast with the expected worsening of fatigue during RT, previous studies (3, 
38, 39) have reported a lessening of cancer-related fatigue.  
In the present study, the majority of the participants had received chemotherapy before RT. 
Fatigue associated with chemotherapy has been documented to be more intense than with RT 
(40). Prior chemotherapy experience could shift in patients’ standard in judging the symptom 
severity such that fatigue induced by RT was judged to be milder. Participants might plausibly 
feel less fatigued over time after the completion of chemotherapy. Smets et al. (41) noted that 
patients might gradually cope better with treatment-related demands such as daily trips to the 
clinic and meeting social obligations over the course of RT, making the patients feel less fatigued. 
Besides, we did not ask the participants in the control group to refrain from engaging in 
symptom relief measures during the study. It is possible that participants in the control group 
might have performed exercise on their own during the study period, leading to a decrease in 
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their fatigue levels. 
There were several study limitations. Since the study sample included only ambulatory 
patients, our findings cannot be generalized to those who are less mobile. Patients who were in 
severe fatigue or pain might lack the stamina or motivation to join the program. This may lead to 
sampling bias and response bias and underestimation of the severity of the symptoms in the 
sample. An interesting finding is that participants who dropped out of the study were 
significantly younger and displayed better sleep quality and quality of life. This may suggest that 
these participants were already accessing social support and the intervention was felt to be of less 
use to them. Future studies should explore the effects of DMT on patients who are more impaired 
by fatigue or pain.  
Besides, the time constraint of RT treatment limited the duration of the intervention and the 
data collection interval. This might potentially hamper bigger changes to be observed in 
outcomes. Nevertheless, the DMT intervention had a high completion rate and was well received 
by most participants. No participants reported any adverse effects of DMT throughout the study. 
The modest effect sizes of DMT found in this study could be explained by brevity of the 
intervention period. A prospective study with a longer DMT program that covers the 
post-treatment period and a longer follow-up period would elucidate the potential benefits and 
sustainability of DMT. Future studies should examine optimal treatment dose and duration for 
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18 
DMT interventions on cancer patients. 
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Figure Legends  
Fig. 1. CONSORT flowchart of the study. 
Fig. 2. Estimated trajectories of perceived stress and pain symptoms over RT. 
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Table 1  Demographic and clinical characteristics of study participants at 
baseline 
 DMT (n = 69) Control (n = 70)   
 n (%) n (%) χ2 p 
Education level     
Secondary or below 43 (62) 47 (67) 
0.35 .55 
Tertiary 26 (38) 23 (33) 
Marital status     
Single 22 (32) 30 (43) 
1.79 .18 
Married  47 (68) 40 (57) 
Cancer stage     
0  5 (8) 4 (6) 
0.68 .88 
I 17 (25) 18 (26) 
II 27 (40) 31 (46) 
III 18 (27) 15 (22) 
Surgery type     
Mastectomy 27 (39) 30 (43) 
0.20 .66 
Lumpectomy 42 (61) 40 (57) 
Chemotherapy     
No 13 (19) 16 (23) 
0.34 .56 
Yes 56 (81) 54 (77) 
 M (SD) M (SD) t p 
Age (in years)  48.6 (7.7) 49.1 (8.7) -0.40 .69 
Days of RT received 9.2 (8.0) 9.7 (8.4) -0.40 .69 
Note. DMT = Dance movement therapy.  
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Table 2  Descriptive statistics of outcome variables by treatment group 
 DMT group  
 
Control group 
 
Outcome 
Baseline 
(n = 69) 
Follow up 
(n =66) 
Change 
% 
Baseline 
(n = 70) 
Follow up 
(n = 64) 
Change 
% 
 M (SD) M (SD)   M (SD) M (SD)  
Perceived stress 19.4 (4.3) 18.4 (4.6) -5.2%  19.2 (4.8) 19.5 (4.0) +1.6% 
Anxiety 6.2 (3.1) 6.3 (3.8) +1.6%  5.7 (3.3) 5.7 (3.0) - 
Depression 5.5 (3.4) 5.5 (3.7) -  5.8 (4.0) 5.5 (3.4) -5.0% 
Fatigue severity 5.3 (2.3) 4.9 (1.9) -7.6%  4.9 (2.2) 4.6 (2.3) -6.0% 
Fatigue interference 3.9 (2.2) 3.4 (2.2) -12.8%  3.8 (2.2) 3.4 (2.4) -10.5% 
Pain Severity 3.0 (2.1) 2.9 (2.0) -3.7%  2.5 (2.3) 3.1 (2.2) +24.0% 
Pain interference 2.7 (2.2) 2.6 (2.2) -3.7%  2.1 (2.1) 2.6 (2.3) +23.8% 
Sleep disturbance 7.5 (3.9) 7.1 (3.9) -5.3%  7.3 (4.2) 7.5 (4.2) +2.7% 
Quality of life 97.1 (18.8) 98.9 (20.0) +2.0%  97.9 (18.1) 97.8 (18.4) -0.1% 
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Table 3  Estimates of DMT effects on outcome variables 
Change in outcome β SE z p d 
Perceived stress -0.167 0.081 -2.07 .039* 0.33 
Anxiety 0.039 0.085 0.45 .65 0.08 
Depression 0.057 0.090 0.63 .53 0.11 
Fatigue severity 0.003 0.092 0.03 .98 0.01 
Fatigue interference -0.071 0.090 -0.79 .43 0.14 
Pain severity -0.181 0.086 -2.11 .035* 0.36 
Pain interference -0.173 0.087 -1.98 .048* 0.35 
Sleep disturbance -0.098 0.084 -1.17 .24 0.20 
Quality of life 0.048 0.087 0.55 .58 0.10 
Note. β = standardized regression estimates; SE = standard error; d = effect 
size on between-group difference in change; * p < .05. 
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